Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie
- Deal value of US$ 1 billion with US$ 130 million upfront
- Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing
- Syndesi’s lead program SDI-118 to be accelerated by AbbVie to the benefit of patients suffering from cognitive impairment associated with a range of neurodegenerative and neuropsychiatric diseases
Copenhagen, Denmark – Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics (‘Syndesi’) has been acquired by AbbVie (NYSE: ABBV) for up to US$1 billion in total deal value with US$ 130 million upfront.
